NASDAQ: CAPSCapstone Holding Corp Stock
$2.03+0.01 (+0.5%)
Updated Apr 21, 2025
CAPS Price
$2.03
Fair Value Price
N/A
Market Cap
$10.54M
52 Week Low
$1.65
52 Week High
$4.18
P/E
-0.06x
P/B
-3.45x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$44.88M
Earnings
-$2.56M
Gross Margin
21.3%
Operating Margin
-1.42%
Profit Margin
-12.2%
Debt to Equity
-6.76
Operating Cash Flow
$4M
Beta
1.5
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CAPS's potential to beat the market
- CAPS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CAPS
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CAPS news, forecast changes, insider trades & much more!
CAPS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CAPS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CAPS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CAPS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CAPS's Earnings (EBIT) of -$638.00k... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CAPS due diligence checks available for Premium users.
Valuation
CAPS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
-184.27x
Market
27.14x
CAPS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.45x
Industry
4.04x
CAPS's financial health
Profit margin
Revenue
$10.3M
Net Income
-$1.1M
Profit Margin
-11%
CAPS's Earnings (EBIT) of -$638.00k... subscribe to Premium to read more.
Interest Coverage Financials
CAPS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$47.2M
Liabilities
$20.7M
Debt to equity
-6.76
CAPS's short-term assets ($12.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAPS's short-term assets ($12.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAPS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CAPS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.8M
Investing
-$19.0k
Financing
-$2.8M
CAPS's operating cash flow ($3.82M)... subscribe to Premium to read more.
Debt Coverage Financials
CAPS vs Biotech Stocks
Capstone Holding Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.